CompletedEarly Phase 1NCT03584724

Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis

Studying Uveitis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eye Pharma
Principal Investigator
Pia Allegri
S.S. Uveitis Center, Rapallo Hospital, Genoa- Italy
Intervention
Norflo Oro(drug)
Enrollment
49 target
Eligibility
18 years · All sexes
Timeline
2018 – 2020

Study locations (1)

Collaborators

Bascom Palmer Eye Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03584724 on ClinicalTrials.gov

Other trials for Uveitis

Additional recruiting or active studies for the same condition.

See all trials for Uveitis →

← Back to all trials